Analysts forecast that Omnicell, Inc. (NASDAQ:OMCL) will report $214.65 million in sales for the current quarter, Zacks reports. Three analysts have provided estimates for Omnicell’s earnings. The highest sales estimate is $215.15 million and the lowest is $214.03 million. Omnicell posted sales of $197.94 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 8.4%. The business is expected to report its next quarterly earnings report on Thursday, February 7th.
According to Zacks, analysts expect that Omnicell will report full year sales of $790.20 million for the current financial year, with estimates ranging from $789.58 million to $790.71 million. For the next year, analysts anticipate that the firm will post sales of $878.10 million, with estimates ranging from $866.79 million to $884.65 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that that provide coverage for Omnicell.
OMCL has been the subject of several research analyst reports. Craig Hallum lifted their target price on Omnicell from $65.00 to $80.00 and gave the stock a “buy” rating in a research note on Monday, September 17th. Zacks Investment Research upgraded Omnicell from a “sell” rating to a “hold” rating in a research note on Monday, August 13th. Benchmark lifted their target price on Omnicell from $66.00 to $79.00 and gave the stock a “buy” rating in a research note on Friday, October 5th. BidaskClub upgraded Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 28th. Finally, MED lifted their target price on Omnicell from $59.00 to $71.00 and gave the stock an “in-line” rating in a research note on Monday, October 22nd. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Omnicell currently has an average rating of “Buy” and an average target price of $69.86.
In related news, Director James T. Judson sold 5,000 shares of the business’s stock in a transaction on Tuesday, September 4th. The stock was sold at an average price of $68.90, for a total value of $344,500.00. Following the completion of the sale, the director now directly owns 34,952 shares in the company, valued at approximately $2,408,192.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Peter J. Kuipers sold 5,574 shares of the business’s stock in a transaction on Monday, September 10th. The shares were sold at an average price of $68.87, for a total value of $383,881.38. Following the completion of the sale, the chief financial officer now owns 51,542 shares of the company’s stock, valued at $3,549,697.54. The disclosure for this sale can be found here. Insiders sold a total of 24,277 shares of company stock valued at $1,654,248 over the last 90 days. 3.71% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. SFE Investment Counsel boosted its stake in Omnicell by 34.0% in the 2nd quarter. SFE Investment Counsel now owns 9,743 shares of the company’s stock valued at $511,000 after purchasing an additional 2,471 shares during the period. Kopp Investment Advisors LLC raised its holdings in Omnicell by 2.6% in the 2nd quarter. Kopp Investment Advisors LLC now owns 69,077 shares of the company’s stock valued at $3,623,000 after acquiring an additional 1,757 shares in the last quarter. Janus Henderson Group PLC raised its holdings in Omnicell by 52.1% in the 2nd quarter. Janus Henderson Group PLC now owns 1,513,979 shares of the company’s stock valued at $79,408,000 after acquiring an additional 518,824 shares in the last quarter. Zebra Capital Management LLC acquired a new position in Omnicell in the 2nd quarter valued at $802,000. Finally, West Coast Financial LLC raised its holdings in Omnicell by 3.7% in the 3rd quarter. West Coast Financial LLC now owns 115,580 shares of the company’s stock valued at $8,310,000 after acquiring an additional 4,126 shares in the last quarter. Institutional investors and hedge funds own 98.80% of the company’s stock.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications.
Recommended Story: Hedge Funds – How They Work For Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.